Overview

Tecarfarin Anti-Coagulation Trial (TACT)

Status:
Unknown status
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
TACT is a "real world" randomized controlled trial of tecarfarin, a novel vitamin K antagonist, vs. warfarin. The quality of anticoagulation control will be compared for the two groups of subjects who require chronic oral anticoagulation for a broad panel of indications.
Phase:
Phase 3
Details
Lead Sponsor:
Armetheon Inc
Espero Biopharma
Treatments:
Vitamin K
Vitamins
Warfarin